Provectus Biopharmaceuticals, INC 8-K filings

Provectus Biopharmaceuticals provided an update on its clinical development, regulatory, drug discovery, manufacturing, IP, and business development activities at its 2026 Annual Meeting of Stockholders.

Provectus Biopharmaceuticals, Inc. announced an extension of the automatic conversion date for its Series D and D-1 Convertible Preferred Stock to December 31, 2028.

Provectus Biopharmaceuticals, Inc. announced that its stockholders approved all five proposals at the annual meeting on June 18, 2025, including the election of directors, executive compensation, auditor ratification, and authorization for a reverse stock split.

Provectus Biopharmaceuticals, Inc. announced it will provide updates on its clinical development, regulatory affairs, and corporate activities during its annual meeting of stockholders on June 18, 2025.

Provectus Biopharmaceuticals replaced its independent registered public accounting firm from Marcum LLP to CBIZ CPAs P.C. following CBIZ's acquisition of Marcum's attest business.

Provectus Biopharmaceuticals has approved a financing plan to raise up to $10 million through convertible promissory notes to fund its drug development program and general expenses.

Provectus Biopharmaceuticals has transferred its exclusive license for photodynamic antimicrobial therapy in ophthalmology to its majority-owned subsidiary, VisiRose, Inc.

Provectus Biopharmaceuticals has formed a new subsidiary, VisiRose, to develop and commercialize a novel treatment for eye infections using its Rose Bengal Sodium technology.

Provectus Biopharmaceuticals has granted stock options to its executive team and independent directors, and increased the annual base salary of its CFO, Heather Raines.

Provectus Biopharmaceuticals will provide updates on its clinical development, research, regulatory affairs, manufacturing, and corporate development during its Fourth Quarter 2024 Investor Update on November 14, 2024.

Provectus Biopharmaceuticals will convert $2.13 million in accrued director fees into preferred stock.

Provectus Biopharmaceuticals has approved a financing plan to raise up to $10 million through convertible promissory notes to fund its drug development program and general expenses.

Provectus Biopharmaceuticals has entered into a conversion agreement with Vice Chairman and President Dominic Rodrigues, involving the exchange of Series D preferred stock for Series D-1 preferred stock and amendments to the company's charter.

Provectus Biopharmaceuticals held its annual meeting on June 20, 2024, where stockholders voted on and approved several key proposals, including the election of directors, ratification of the accounting firm, and authorization for a reverse stock split.

Provectus Biopharmaceuticals updated shareholders on its clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities at its annual meeting.

Provectus Biopharmaceuticals has appointed Ed Pershing as CEO and Dominic Rodrigues as President, effective April 16, 2024, as part of its strategy to enhance shareholder value.

Provectus Biopharmaceuticals has secured an exclusive worldwide license from the University of Miami to develop a photodynamic antimicrobial therapy for eye infections.

Provectus Biopharmaceuticals has announced the resignation of its Chief Operating Officer, Bruce Horowitz, and the appointment of Dominic Rodrigues as chief operations consultant, resolving a dispute with Horowitz in the process.

Provectus Biopharmaceuticals hosted a conference call on February 22, 2024, to provide company updates, accompanied by a slide presentation.

Provectus Biopharmaceuticals will host a conference call on February 22, 2024, to provide company updates.